Brief Title
Oxytocin in MRI-HIFU
Official Title
Use of Oxytocin in MRI-HIFU Treatment
Brief Summary
Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
NPV
Condition
Fibroid
Intervention
Oxytocin
Study Arms / Comparison Groups
Patients treated with oxytocin during MRI-HIFU
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
100
Start Date
February 1, 2019
Completion Date
January 1, 2021
Primary Completion Date
December 30, 2019
Eligibility Criteria
Inclusion Criteria: - Patients undergoing MRI-HIFU -treatment - Patients assessed for suitability to MRI-HIFU treatment - willingness to participate in trial Exclusion Criteria: - Known allergy to Syntocinon/oxytocin - Elevated blood pressure - ischemic heart disease - Long QT- interval
Gender
Female
Ages
18 Years - 50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, ,
Location Countries
Finland
Location Countries
Finland
Administrative Informations
NCT ID
NCT03937401
Organization ID
T366/2017
Responsible Party
Sponsor
Study Sponsor
Turku University Hospital
Study Sponsor
, ,
Verification Date
May 2019